Letter to the editor concerning first-line therapy with afatinib - an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations.

Krawczyk, Pawel; Powrózek, Tomasz; Nicos, Marcin; Milanowski, Janusz

Krawczyk, Pawel; Powrózek, Tomasz; Nicos, Marcin; Milanowski, Janusz.

Afiliação

Krawczyk P; Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Poland.
Powrózek T; Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Poland.
Nicos M; Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Poland.
Milanowski J; Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Poland.

Contemp Oncol (Pozn) ; 19(3): 250-1, 2015.

Article em En | MEDLINE | ID: mdl-26557768

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2015 Tipo de documento: Article